PSI-6130
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H14FN3O4 |
| Molar mass | 259.23 g/mol g·mol−1 |
| (verify) | |
PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark.[1] Specifically, PSI-6130 inhibits the hepatitis C virus NS5B RNA dependant RNA polymerase.[2]
PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128.[3] R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.[4][unreliable source?]
References
- ^ Clark, J.; et al. (2005). "Design, synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'C-methylcytidine, a potent inhibitor of hepatitis C virus replication". Journal of Medicinal Chemistry. 48 (17): 5504. doi:10.1021/jm0502788. PMID 16107149.
{{cite journal}}: Explicit use of et al. in:|author=(help) - ^ Lieven J Stuyver, Tamara R McBrayer, Phillip M Tharnish, Jeremy Clark, Laurent Hollecker; et al. (2006). "Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication". Antiviral Chemistry & Chemotherapy. 17 (2): 79–87.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ Cole, P.; Castaner, R.; Bolos, J. (2009). "R-7128: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection". Drugs of the Future. 34 (4): 282–290.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "INFORM-1 (R7227 and R7128) study".